

## ANNOUNCEMENTS



### PREDICTIVE MODELING IN PROSTATE CANCER

April 17-19, 2008  
Venice, Italy

Chair L Denis, BE, P Scardino, US  
Host Chair R Valdagni, IT  
Conference Co-ordinator G Conti, IT

#### Topics

Genomic and biomolecular approaches to outcome prediction

Histopathology and systems pathology for building predictive models

Predictive models in

- diagnosing prostate cancer and indolent disease
- surgery (before and after)
- radiotherapy (external and brachithrapy)
- treatment toxicities
- medical oncology and palliative care
- andrology
- long term survival

#### For further information

European School of Oncology  
Tel +39 02 8546 4527  
Fax +39 02 8546 4545  
e-mail [rdemartini@esoncology.org](mailto:rdemartini@esoncology.org)

Website: [www.cancerworld.org/eso](http://www.cancerworld.org/eso)



### OECI 2008 SCIENTIFIC WEEK

May 20-24, 2008  
Genoa, Italy

#### May 21-22

#### TRANSFOG (TRANSlational and Functional Onco Genomics) Symposium

The Symposium is based on the results coming from an EC-funded integrated project aimed at establishing Europe's leadership in the field of cancer genomics. A joint effort has been developed involving leading academic and industrial groups towards the systematic identification and functional characterisation of novel cancer genes with a high diagnostic and therapeutic potential in breast, colon and lung cancer.

#### May 22

#### International Clinical Trials' Day on Biotherapy of Cancer

Biotherapy of cancer will be the focus of the OECI 2008 edition of the ECRIN traditional yearly celebration of the first randomized clinical trial. In the same day representatives of European networks dedicated to cancer biotherapies will exchange and discuss their experience.

#### May 23

#### OECI 2008 Scientific Conference

#### Discovering new worlds in medicine: towards nanoapplication in cancer prevention and treatment

Nanoscience offers a chance to make significant progress in the diagnosis and treatment of cancer. The interaction in real time with normal and cancer cells at molecular and cellular level is being applied to two broad areas: the development of nanovectors for drug (or imaging agents) delivery to cancer cells and the design of nanosensor devices for early detection of cancer biological signatures.

During the conference, new forms of "personalised" medicine will be discussed focusing on nanotech cancer applications to early detection and treatments. The conference represents an opportunity to meet some of the leading scientists in applied nanosciences and EC officers.

#### SCIENTIFIC PROGRAMME

#### Morning Session

Welcome and opening *Enrico Garaci and Ulrik Ringborg*

Innovation of cancer care in the 21<sup>st</sup> century.

The role of European collaboration *Umberto Veronesi*

Welcome by the EU DG Health and Consumer Protection *Paola Testori Coggi*

Opportunities in the 7th FP and the Nanomedicine Platform *Renzo Tomellini*

Nanotechnologies: an overview *Mauro Ferrari*

#### Section 1 Application to cancer prevention and diagnosis *Chair U Ringborg and D de Valeriola*

Optical biopsy of cancer: nanotechnological aspects *Ricardas Rotomskis*

Nanopore devices and nanoscale microscopies for genomics *Ugo Valbusa*

Point-of-care systems for rapid DNA quantification in oncology *Marco Bianchessi*

MR and iron magnetic nanoparticles: imaging opportunities in preclinical and translational research  
*Carlo Emanuele Neumaier*

**Section 2 Application to cancer treatment**  
**1<sup>ST</sup> part Chair T Tursz and G Storme**

Drug Design: an overview on modern structure-based drug design  
*Tom Blundell*

ABCD nanoparticles for the delivery of therapeutic nucleic acids and imaging agents to tumour  
*Andrew Miller*

Apoptosis chip for testing of drugs on breast cancer cells  
*Albert van den Berg*

**Afternoon Session**

**Section 2 Application to cancer treatment**  
**2<sup>nd</sup> part Chair A Llobart-Bosch and K Nilsson**

Drug delivery: application of liposomal drugs to neuroectodermal cancer treatment  
*Mirco Ponzoni*

siRNA nanoformulation is efficient in mouse xenografted tumors expressing human junction oncogenes  
*Claude Paul Malvy*

Transformation of novel nanomaterials to clinically viable nanomedicine tools: the case of carbon nanotubes  
*Kostas Kostarelos*

Nanoparticles for tumour imaging and tumour gene delivery  
*Daniel Scherman*

Use of nanoparticles for cerebral cancer  
*Jorg Kreuter*

Therapeutic reactive oxygen generation using fullerenes  
*Peter Scharff*

**Section 3 Technology assessment and risk management Chair W Van Harten**

Assessment of new early phase nanotechnologies  
*W van Harten*

Nanoparticles: potential cancer risks and research needs  
*Vincent Coglianò*

**Conclusions** *Marco A Pierotti*

**For further information and registration**  
<http://www.oeci-eeig.org> - [focalpoint.acc@istge.it](mailto:focalpoint.acc@istge.it)



*International Conference on*  
**CANCER GENOTYPES  
AND CANCER  
PHENOTYPES**

July 4-5, 2008  
*Palazzo Congressi, Florence, Italy*

This meeting will focus on the molecular basis of cancer, and particularly on the identification of the genetic mechanisms that underlie neoplastic growth, invasiveness and metastasis. An *ad hoc* session will be centered on highlighting, for individual types of tumors, clinical questions that are ripe for being tackled scientifically.

*Confirmed speakers include*  
David Araten, *New York*  
Andrea Bacigalupo, *Genova*  
René Bernards, *Amsterdam*  
Günter Blobel, *New York*  
Sydney Brenner, *Cambridge/San Diego*  
Paolo Comoglio, *Torino*  
Carlo Croce, *Columbus*  
Albert de la Chapelle, *Columbus*  
Angelo Di Leo, *ITT, Prato*  
Alfredo Falcone, *ITT, Livorno*  
John Goldman, *London*  
Tim Hunt, *South Mimms*  
Christoph Klein, *Regensburg*  
Joan Massagué, *New York*  
Salvatore Oliviero, *ITT, Siena*  
Pier Paolo Pandolfi, *Boston*  
Pier Giuseppe Pelicci, *Milano*  
Juan Rosai, *Milano*  
Michel Sadelain, *New York*  
Massimo Santoro, *Napoli*  
Cora Sternberg, *Roma*

Participation is open to all. Application forms are available on the ITT site ([www.itt.toscana.it](http://www.itt.toscana.it)). Early registration is recommended because members of ITT will have priority. Submission of abstracts of scientific research will be welcome. Some abstracts will be selected for oral presentation during the Meeting.

**For further information**  
Istituto Toscano Tumori:  
Tel +39 055 4385213 Fax +39 055 4385252  
e-mail [daniela.chiaramonte@regione.toscana.it](mailto:daniela.chiaramonte@regione.toscana.it)